The agency is taking action to curb the illicit online trade of unregulated and unapproved ketamine products through a slew of warning letters.
Sino Biopharmaceutical will receive an upfront payment of $200m from AstraZeneca.
The partnership will connect Evogene’s AI-based ChemPass AI with the BCDD’s laboratory infrastructure.
The biotech’s potential launch on the public markets would help fuel development of its clinical-stage, melanocortin-focused pipeline.
Vivani’s NanoPortal technology delivers medication steadily over long periods of time.
The status was granted by the FDA's Office of Orphan Products Development and Office of Pediatric Therapeutics.
